Pharmacological, optical, and combined approaches to myopia control in Bulgarian children: a longitudinal study
DOI:
https://doi.org/10.2478/AMB-2026-0053Keywords:
myopia control, pediatric ophthalmology, defocus lenses, atropine 0.01%Abstract
Abstract. This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.
References
Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. British Journal of Ophthalmology. 2024;108(8):1021–1029.
Li Xiaotong, Li Lihua, Qin Wen, et al. Urban Living Environment and Myopia in Children: A 2-Year Cohort Study of 177,894 Elementary Schoolchildren in Tianjin, China. JAMA Network Open. 2023;6(12):e2346999.
Zhang X, Li Y, Zhang J, et al. Prevalence and temporal trends in myopia and high myopia in Chinese children and adolescents: a systematic review and meta-analysis with projections to 2050. The Lancet Regional Health – Western Pacific. 2025;59:100443.
Moreira-Rosário A, Lanca C, Grzybowski A. Prevalence of myopia in Europe: a systematic review and meta-analysis of data from 14 countries. The Lancet Regional Health – Europe. 2025;59:101319.
Dragomirova M, Antonova A, Stoykova S, et al. Myopia in Bulgarian school children: prevalence, risk factors, and healthcare coverage. BMC Ophthalmology. 2022;22(1):248.
Valcheva K, Ivancheva V. Prevalence and control of myopia among children in Pleven, Bulgaria. Trakia Journal of Sciences. 2022;20(2):152–157.
Vidinova C, Koeva A. Myopia – risk factors, prevalence in Bulgarian schools, and prevention. Acta Medica Bulgarica. 2024;51(4):29–32.
Lee Y, Keel S, Yoon S. Evaluating the effectiveness and scalability of the WHO MyopiaEd digital intervention program in South Korea: a mixed-methods study. JMIR Public Health and Surveillance. 2024;10:e40323. DOI: 10.2196/40323.
Lawrenson JG, Shah R, Huntjens B, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;2:CD014758.
Yu Y, Liu J. The eff ect of 0.01% atropine and orthokeratology on ocular axial elongation for myopia children: a meta-analysis. Medicine (Baltimore). 2022;101(18):e29191.
Zadnik K, Schulman E, Flitcroft I, et al. Safety and efficacy of 0.01% and 0.02% atropine for treatment of childhood myopia: 36-month results from the CHAMP trial. JAMA Ophthalmol. 2023;141(10):1005–1015.
Pérez-Flores I, Macías-Murelaga B, Barrario-Barrio J; GTAM Group. Age-related results over 2 years of the Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2023;13(1):16310.
Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2. Ophthalmology. 2020;127(2):168-177.
Aller TA, Liu M, Wildsoet CF. Myopia control with bifocal contact lenses: a randomized clinical trial. Optom Vis Sci. 2016;93(4):344–352.
Ma JX, Tian SW, Liu QP. Eff ectiveness of peripheral defocus spectacle lenses in slowing myopia progression: a systematic review. Front Pediatr. 2022;10:952256.
Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res. 2018;62:134–149.
Tang T, Lu Y, Li X, et al. Comparison of the long-term effects of atropine in combination with orthokeratology and defocus lenses. Eye (Lond). 2024;38(9):1660–1667.
Haarman AEG, Enthoven CA, Tideman JWL, et al. The Complications of Myopia: A Review and Meta-Analysis. IOVS. 2020;61(4):49.
Sindal MD, Behera SP, Chaitanya V. Pediatric retinal detachments in eyes with extreme high myopia. Oman J Ophthalmol. 2025;18(1):40–43.
Guemes-Villahoz N, Talavero-González P, et al. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results. Br J Ophthalmol. 2025;0:1–7.
Dahlmann-Noor A, Jaselsky A, Whiting C, et al. Increasing prevalence of myopia in patients undergoing retinal detachment repair: an 11-year service evaluation. Eye. 2024;38:1231–1232.
Ng DS, Chan LK, Lai TY. Myopic macular diseases: a review. Clin Exp Ophthalmol. 2023;51(3):229–242.
Du Y, Meng J, He W, et al. Complications of high myopia: an update from clinical manifestations to underlying mechanisms. Adv Ophthalmol Pract Res. 2024;4(3):156–163.
Chen C-W, Yao J-Y. Evaluation of risk factors for childhood myopia progression: a systematic review. Indian J Ophthalmol. 2024;72(1):2341–2352.
Yu M, Hu Y, Han M, et al. Global risk factor analysis of myopia onset in children: a meta-analysis. PLOS ONE. 2023;18(9):e0291470.
Fernández Irigaray L, Torres R, Zanutigh V, et al. Lifestyle and sleep-related behaviours in children with myopia. BMC Ophthalmol. 2025;25:97.
Karim MS, Shukla H, Mishu NI, et al. Impact of screen time reduction and outdoor activities on myopia. J Biosci Public Health. 2025;1(1):1-12.
Joachimsen L, Farassat N, Bleul T, et al. Side effects of topical atropine 0.05% compared to 0.01%. Int Ophthalmol. 2021;41(6):2001–2008.
Akagün N, Altıparmak UE. Evaluation of Reasons for Discontinuation of Atropine 0.01%. Turk J Ophthalmol. 2025;55(2):61-66.
Wenyan Xu, Xiaoman Li, Jianing Zhang, et al. The Peripheral Defocus Designed Spectacle Lenses Might Increase Astigmatism. Trans Vis Sci Tech. 2025;14(3):8. https://doi.org/10.1167/tvst.14.3.8.
Bullimore MA, Ritchey ER, Shah S, et al. The Risks and Benefits of Myopia Control. Ophthalmology. 2021;128(11):1561-1579. https://doi.org/10.1016/j.ophtha.2021.04.032.
Chia A, Chua WH, Cheung YB, et al. ATOM-2 Study. Ophthalmology. 2012;119(2):347–354.
Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology. 2019;126(1):113–124.
Lam CSY, Tang WC, Tse DY, et al. DIMS spectacle lenses slow myopia progression: a 2-year trial. Br J Ophthalmol. 2020;104(3):363–368.
Lam CSY, Tang WC, Lee PH, et al. DIMS lens: 3-year follow-up study. Br J Ophthalmol. 2022;106(8):1110-1114.
Huang Z, Chen XF, He T, et al. Synergistic effects of DIMS and atropine. Sci Rep. 2022;12:22311.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 G. Dimitrov, G. Dimitrova, A. Levi, N. Veleva, O. Mladenov, Y. Kaneva, A. Oscar (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.


Journal Acta Medica Bulgarica